The appointments are part of RBS CIB’s drive to enhance the range of services it offers to clients in the healthcare sector. Makinson and Weeks will work to build the team’s proposition into the fast-growing medical technology (‘medtech’) and pharmaceutical industries, whilst also continuing to focus on corporates in the private care and hospital spaces.
Makinson moves to her new position from RBS’s Structured Finance Corporates team where she played a lead role in the recent financings for Abbey Total Care Group and of Grant Thornton UK LLP. Prior to this she has spent time in RBS’s Markets and International Banking (M and IB) Loan Market Origination team, having joined Royal Bank of Scotland in 2008 on its Corporate Banking Graduate Programme.
Weeks joins the healthcare and pharmaceuticals team from RBS’s Global Restructuring Group. As corporate relationship director, his role was to pursue turnaround opportunities for financially distressed corporates, focusing on operational and balance sheet restructures. Paul started his career as a graduate trainee at RBS Insurance and has since worked as strategy manager for RBS Major Corporate Banking and assistant director for RBS Property Structured Finance.
Based at the bank’s Bishopsgate offices in London, RBS CIB’s healthcare and pharmaceuticals team works with a wide range of organisations from care homes and dental practices to suppliers of medical devices. It helps them with a variety of financing requirements including the provision of world-class day-to-day operational banking through to funding growth via acquisition and capital expansion.
"I am absolutely delighted to be joining the healthcare and pharmaceuticals team. It is a fast growing and dynamic part of RBS and, capitalising on the team’s already strong presence in the market, we have exciting expansion plans for the division. I look forward to working with my new colleagues and clients to grow the business."
"The healthcare and pharmaceuticals team already has an impressive track record, counting Nuffield Hospitals and the Priory Group among its clients. This is an exciting time for the division, and our expansion of the business into the pharmaceutical and medtech sectors further underlines our commitment to companies within the healthcare industry."